



## Original Article

### Diagnostic Utility of Serum Amyloid A and Salivary C-Reactive Protein in Diagnosis of Late Onset Sepsis in Neonates. A Prospective Case Control Study

Nagwa M. Sabry Mahmoud<sup>1\*</sup>, Gamal Baheeg Mohamed<sup>1</sup>, Nagwa Ismail Okaily<sup>2</sup>, Manar Anwar Abd-Elaziz<sup>1</sup>, Nageh Shehata Ismail<sup>1</sup>

DOI: 10.21608/anj.2024.300074.1094

\*Correspondence: Department of pediatrics, Faculty of Medicine, Minia University, Egypt

Email: dr\_nagwa163@ mu.edu.eg

Full list of author information is available at the end of the article

#### Abstract

**Background:** Neonatal sepsis is a global mortality risk, necessitating early identification and use of reliable biomarkers, despite ongoing controversy surrounding their use. **Objectives:** The study aimed to evaluate the values of salivary C-reactive protein (CRP) and serum amyloid A (SAA) for the diagnosis of neonatal sepsis. **Patients and methods:** The study involved 80 neonates with late-onset sepsis (LOS) and 40 healthy controls from June 2022 to October 2023. They underwent a detailed perinatal history, physical examination, complete blood count (CBC), blood culture, salivary CRP, SAA, and comprehensive metabolic panel (CMP) included an electrolyte panel, renal and liver function tests, glucose and calcium. We evaluated salivary CRP and SAA before initiating antibiotic therapy. A positive blood culture confirmed the diagnosis of sepsis. We determined the biomarker diagnostic values using receiver operating characteristic curve (ROC curve) analysis and assessed their sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and diagnostic accuracy. **Results:** Significant differences between cases and controls regarding salivary CRP, serum CRP, and SAA levels (p value <0.001) were present. Cases had higher mean salivary CRP (1.6) and SAA (26.4) levels than controls (0.16) and (3.1) respectively. Additionally, cases had a significantly higher mean serum CRP level (53.4) compared to controls (0.9). A moderately positive correlation was found between salivary CRP, serum CRP, and SAA ( $r = 0.70$ ), with a significant p value <0.001. **Conclusion:** The study suggests salivary CRP can be a valuable noninvasive biomarker for late-onset neonatal sepsis diagnosis, with comparable results to SAA and serum CRP.

**Key words:** Salivary CRP, serum amyloid A, neonatal sepsis, biomarkers, newborn.

## Introduction

Neonatal sepsis is a bloodstream bacterial infection causing severe clinical symptoms, often leading to death or long-term deficits. Death can occur in 3–4% and up to 24% of neonates born in industrialized countries. [1] and in the developing world respectively [2] with long-term neurodevelopmental issues such as cerebral palsy and vision impairment among survivors.[3] Neonatal sepsis is classified as early-onset sepsis (EOS) if diagnosed within 72 hours after birth or late-onset sepsis (LOS) if diagnosed after this period. [4] EOS is primarily caused by vertical transmission of *Escherichia coli* and Group B *Streptococcus* from women with chorioamnionitis, prolonged membrane rupture, and GBS colonization. Pathogens acquired nosocomially often cause LOS in neonates at risk due to prematurity, invasive instrumentation, parenteral nutrition, and mechanical ventilation. [5,6] In developed countries, the

incidence of EOS and LOS is no lower than 0.3–0.8 cases per 1000 live births, and in developing countries, it is about 6 cases per 1000 live births. [7-9] Factors such as birth weight and gestational age also influence the risk of neonatal sepsis development. [10,11] However, studies have revealed that only 53% of enrolled infants identify EOS, leaving many documented cases of neonatal sepsis undetected specially in preterm neonates. [12,13] Neonates have an immature immune system, increasing their risk of infection, as well as varying inflammatory and clinical responses to infectious agents. This explains why the criteria used to define sepsis in adults do not apply to neonates. [14] Early-stage symptoms of sepsis in neonates are subtle and non-specific, often common to other conditions; regardless of, whether they are infectious, metabolic, or traumatic. [15,16] Therefore, the definition of sepsis in neonates is still lacking, and several scientific institutions have suggested specific criteria for

proper identification. We consider these parameters and child conditions to create a risk calculator that identifies which children require treatment. A risk calculator has been created by considering many parameters and conditions of the neonates to determine the need for treatment of neonatal sepsis. [17,18] Antibiotics are the primary treatment for sepsis, but their overuse in neonates has led to various problems, including the emergence of antimicrobial resistance and the promotion of dysbiosis. [19-23] Despite the introduction of stewardship programmes, antibiotic overuse in neonates persists and can lead to the development of life-long health problems. This overuse can lead to life-long health issues such as obesity, type I diabetes, asthma, autism spectrum disorders, necrotizing enterocolitis, and earlier death. [24-26] Early diagnosis of neonatal sepsis can improve outcomes and reduce antibiotic use. An ideal marker should have high sensitivity, specificity, and predictive

values, provide reliable antibiotic therapy information, reduce overuse, prevent bacterial resistance, and be simple to perform, cost-effective, and comparable across laboratories.[27] Neonatal sepsis diagnosis traditionally relies on positive blood cultures, but these have long turnaround times and low sensitivity, leading to inappropriate antibiotic therapy. Invasive procedures and inoculant volume condition blood cultures, leading to negative results. [28,29] Advances in molecular methods like polymerase chain reaction (PCR), real-time PCR, pyrosequencing, and microfluidic technology have improved sensitivity and specificity but require specialised biology laboratories and equipment, which are not available in many hospital settings, particularly in the third world. [30,31] A lot of research has looked at white blood cell count (WBC), absolute neutrophil count (ANC), immature-to-total neutrophil ratio (I/T), and platelet count as possible signs of sepsis in newborns. [32-38] The

widespread use of these tests stems from their simplicity, cost-effectiveness, and the absence of advanced laboratory equipment. However, most studies have limitations in design, sample size, and sepsis case definition, limiting the reliability of the results. [36] Maternal and neonatal factors can significantly modify these indices, making differentiation between infected and non-infected babies difficult. [36] Identifying neonatal sepsis markers could improve early diagnosis, improve outcomes, and reduce antibiotic use. Researchers have developed several cytokines and molecular biomarkers for this purpose over the past 30 years, but their widespread use is unlikely due to their high cost and limited benefits. Developing biomarkers could improve the long-term outcomes of sepsis cases. [37,38] CRP is a widely recognized biomarker that is extensively used for diagnosing and monitoring newborn sepsis. Identifying sepsis in its early stages, however, is challenging due to

constraints such as low specificity and a minimum length of 3 days to rise. [39] Salivary CRP is a recently studied measure for diagnosing sepsis. Although research on this marker is still in its early stages, it directly correlates with serum levels of CRP, which is a well-established sign of systemic inflammation. [40] Consequently, researchers are conducting ongoing research to identify reliable indicators for diagnosing newborn sepsis. serum amyloid A (SAA), is an apolipoprotein, produces by the liver under the precise control of IL-1, IL-6, and TNF- $\alpha$  in response to inflammation. [41] In healthy newborns, the usual range for SAA is between 3.2 and 3.4 mg/dL. However, in cases of NS, the concentration is significantly higher, at  $44.4 \pm 57.3$  mg/dL. [42] Multiple studies have suggested that SAA can serve as a biomarker for EOS, demonstrating promising diagnostic capabilities for risk stratification. [43] The study aims to evaluate the diagnostic utility of salivary

CRP as a noninvasive biomarker in neonatal sepsis, its potential use for follow-up, and its accuracy in diagnosing and predicting sepsis. It also assesses the level of SAA in neonates with sepsis, as well as its value in diagnosing sepsis and predicting culture positivity in cases diagnosed with sepsis.

### **Patients and Methods**

This was a case-control study that included 80 neonates (both preterm and full term), 40 of whom had a diagnosis of neonatal sepsis (late-onset sepsis) admitted to the neonatal intensive care unit (NICU) at Minia University Hospital as cases, and 40 apparently healthy, age- and sex-matched neonates as controls . 40 cases were full-term, and 40 cases were preterm neonates. The study took place between June 2022 and October 2023. History, clinical findings, laboratory findings, and blood culture determined the diagnosis of neonatal sepsis. This study included 40 neonates, divided into cases and control groups. There were 20 full-term and 20 preterm

neonates, all with late-onset sepsis . The control group consisted of 40 healthy neonates age-matched with cases who were chosen as any normal healthy newborn, of both genders, of any mode of delivery who attended the hospital for regular follow-up in the well-baby clinic or were admitted to the nursery postnatally with their mother for routine care. In the study, the Minia University neonatal intensive care unit admitted neonates born after 27 weeks gestation and less than 28 days old for sepsis, or those who developed sepsis within the first 28 days of life. The study excluded individuals with known immune system problems in the mother, mothers on immune-modulating drugs, high doses of corticosteroids, or chemotherapy, newborns with potential cancer, oral infections, hypoxia, oral ulcers, metabolic disease, mechanical ventilation, post-surgery cases, and parents who preferred not to have their child in the hospital. The case group had a complete perinatal history, physical

examination, and investigations related to sepsis, such as a blood count, serum CRP, blood culture, salivary CRP, and SAA. They also had routine blood chemistry and renal function tests. on tests. The control group will undergo a comprehensive perinatal history, physical examination, salivary CRP, and SAA.

#### Sampling:

**Blood samples:** To prevent frequent sampling, we collected blood samples during routine investigations. For a complete blood count, we collected one mL in tubes containing EDTA as an anticoagulant. We collected three mL samples for serum CRP, renal function, electrolyte, and SAA in plain tubes, centrifuged them, and stored them at -20 °C.

**Salivary samples:** To avoid contamination with milk, the study collected salivary samples from neonates. The process involved tilting the head forward to draw saliva into the mouth, as well as connecting a syringe to low-wall suction. We collected saliva from

gingival crevices and under tongues, which took 30–45 seconds. Re-term neonates required longer collection times. We placed the samples in Eppendorf tubes to prevent contamination. We centrifuged the samples at 3000 rpm for 15 minutes after collection and stored the supernatant at -20 °C until batch analysis.

**Methodology:** The study involved a blood count using Celltac G, a Japanese hemocytometer, and a microscopic examination of a blood film. We performed blood cultures using Bactec and analysed serum C-reactive protein using GENRUI. We measured serum amyloid A using ELISA.

**Assay procedure for SAA** The BT LAB prepared reagents, standard solutions, and samples for an assay. We stored the strips at a temperature of 2–8 °C, then added the standard to the standard wells, samples to the sample wells, anti-SAA antibody to the sample wells, and streptavidin-HRP to both wells. We incubated the plate for 60 minutes at

37°C, washed it five times, and soaked it for 30 seconds to 1 minute. We added substrate solutions A and B to each well. BT LAB in China measured salivary CRP using ELISA. The assay involved preparing reagents, standard solutions, and samples and incubating them at 37 °C for 60 minutes. We added a standard and sample first, then added an anti-CRP antibody and streptavidin-HRP after that. We washed, soaked, and blotted the plate. SAAfter adding substrate solutions A and B, we incubated the plate in the dark for 10 minutes. top solution was added, and the optical density (OD value) was determined using a microplate reader set to 450 nm.

#### Ethical consent

The study involved neonates' parents, who provided written consent. Minia University's Institutional Review Board and Medical Ethics Committee approved it with approval number 208:1/2022, adhering to the revised Declaration of Helsinki 1975. We conducted the study in accordance with ethical standards.

#### Data management and analysis:

We collected, tabulated, and analysed the data using the SPSS-26 programme for Windows. The Shapiro Walk test was used for normal distribution, and quantitative results were presented as mean±SD. We presented qualitative data as numbers and percents. We used the Student's t test for comparison, and employed Spearman's test and Pearson's correlation coefficient for correlations. We performed ROC curve analysis for the prediction of neonatal sepsis.

#### Results

As demonstrated in Table 1, The study involved 62.6% females and 37.5% Was male with a mean gestational age of 36±2.3. Most cases (82.5%) improved, and 17.5% died. All septic cases had late-onset sepsis, with clinical signs including fever, tachycardia, decreased sucking, apnea, and oxygen need. 32.5% of patients had post-mechanical ventilation, and 45% had a central venous catheter (CVC) via internal jugular vein.

Table 2 The cases had a higher mean salivary CRP (1.6 ng/ml ), higher serum amyloid levels (26.4 µg/ml), and higher mean serum CRP levels (53.4 mg/L) compared to the control 0.16 ng/ml , 3.1 µg/ml and 0.9 mg/L respectively.

The cases had a higher mean TLC ( $15.8 \times 10^3 / \mu\text{l}$ ) than the control ( $11.0 \times 10^3 / \mu\text{l}$ ) and lower mean levels of hemoglobin and platelets (13.2 g/dl and  $166 \times 10^3 / \mu\text{l}$  , respectively) than the control (16.7(g/dl and 264,  $\times 10^3 / \mu\text{l}$  respectively). Table 3 shows the correlation between serum CRP and both salivary CRP and SAA ,there is a moderate positive correlation between salivary CRP and serum CRP ( $r = 0.50$ ); also, a moderate positive correlation was found between serum CRP and SAA ( $r = 0.70$ ), with a significant p value (0.001). As demonstrated in Table 4, there are statistically significant difference between culture positive cases, clinical septic cases and control regarding salivary CRP, serum CRP, SAA and outcome (p value <0.001). In Table (5)

Figures (1,2,3): sensitivity and specificity of salivary CRP for prediction of neonatal sepsis was 100% and 97.5% respectively when level was more than 0.31ng/ml, with significant p value <0.05, also sensitivity and specificity of serum CRP for prediction of neonatal sepsis was 92.5% and 95% respectively when level was more than 9mg/L. When cut off value of serum amyloid more than 4.6µg/ml, it will have a sensitivity and specificity of 100% and 95% respectively for prediction of neonatal sepsis. With significant p value<0.001.

Table 6 and Figure 4 demonstrate that salivary CRP with level >0.65 has a sensitivity and specificity of 97% and 95% respectively for prediction if serum CRP >10.

Table 7 and Figures 5 and 6, showed that salivary and serum CRP can accurately predict culture-positive cases 90% of the time when serum amyloid levels are above 0.96 mg/L and 80% of the time when they are above 18 mg/L, with a p value less than 0.05 .

Table 8 demonstrates that, there are non-statistically significant difference between preterm babies and full term babies regarding salivary CRP, serum CRP and serum amyloid (p value>0.05) as mean salivary CRP was (1.4ng/ml) on preterm neonates compared to (1.7ng/ml) in full term neonates, also mean serum amyloid and serum CRP was lower in preterm (24.5µg/ml and 47mg/L respectively) than in full term babies (28.3 µg/ml and 60mg/L respectively).

As shown in Table 9: The study revealed that 50% of septic patients had no growth, while the remaining 50% had positive blood cultures, predominantly gramme-negative (37.5%). *Klebsiella*

*pneumoniae* (30%) was the most common organism, followed by MRSA and *Acinetobacter*. Only two cases tested positive for *Candida albicans* and CONS.

**Table (1): Demographic data of the septic group**

<b>Demographic data. (N=40)</b>		<b>Descriptive statistics(N-%)</b>
<b>Gestational Age</b>	Mean $\pm$ SD	36 $\pm$ 2.3
	Median (Range)	36.5 (30:40)
	>37 weeks GA, n (%)	20 (50%)
	34-36 weeks GA, n (%)	13 (32.5%)
	32-33weeks GA, n (%)	5 (12.5%)
	<32 weeks GA, n (%)	2 (%)
<b>Sex</b>	Male	15 (37.5%)
	Female	25 (62.6%)
<b>Birth weight</b>	Mean $\pm$ SD	2 $\pm$ 0.65
	(Range)	1.1:3.60
	>2500	13 (25%)
	1500-2499	19 (47.5%)
	1000-1499	8 (20%)
<b>Delivery type</b>	NVD	27 (67.5%)
	CS	13 (32.5%)
<b>Post natal age at which test performed</b>	Mean $\pm$ SD	11.1 $\pm$ 3.6
	Median (Range)	10 (6:20)
<b>Sepsis</b>	Late onset	40(100%)
	Other	0
<b>Outcome</b>	Died	7 (17.5%)
	Improved	33 (82.5%)
<b>Post mechanical ventilation</b>	Yes	13 (32.5%)
	No	27 (67.5%)
<b>CVC</b>	Yes	18 (45%)
	No	22 (55%)
<b>Fever</b>	Yes	14 (35%)
	No	26 (65%)
<b>Tachycardia</b>	Yes	12 (30%)
	No	28 (70%)
<b>Decreased sucking</b>	Yes	25 (62.5%)
	No	15 (37.5%)
<b>Apnea</b>	Yes	16 (40%)
	No	24 (60%)
<b>Need for oxygen</b>	Yes	23 (57.5%)
	No	17 (42.5%)

CVC: central venous catheter, NVD: Normal vaginal delivery, CS: Caesarean section, SD: standard deviation.

**Table (2): Comparison between cases and control as regard SAA, salivary CRP, serum CRP, HB, platelet and TLC.**

Item	Cases (n=40)	Control (n=40)	P value
<b>Salivary CRP (ng/ml)</b>			
▪ Mean ± SD	1.6 ±0.7	0.16±0.6	<0.001*
▪ Median (Range)	1.6(0.6:3)	0.15 (0.1:0.32)	
<b>SAA (µg/ml)</b>			
▪ Mean ± SD	26.4 ±11.2	3.1±0.8	<0.001*
▪ Median (Range)	26.7 (10.9 :49.5)	3 (1.5:4.8)	
<b>Serum CRP (mg/L)</b>			
▪ Mean ± SD	53.4 ±32	0.9±2.5	<0.001*
▪ Median (Range)	48 (0:96)	0 (0:12)	
<b>Hb (g/dl)</b>			
▪ Mean ± SD	13.2±3.1	16.7±1.5	<0.001*
▪ Median (Range)	12.8 (5.3:21)	16.8 (12.4:19.4)	
<b>TLC (×103 / µl)</b>			
▪ Mean ± SD	15.8±9300	11.0±2500	0.003*
▪ Median (Range)	14.0 (2800:47000)	11.0(6600:16300)	
<b>Platelet (x103/ µl)</b>			
▪ Mean ± SD	166±100	264.3±56.5	<0.001*
▪ Median (Range)	160 (11:400)	259 (182:410)	

Significant at p value<0.05, SD:Standard deviation, SAA: Serum Amyloid A, Hb : Hemoglobin  
TLC: Total Leukocytic Count

**Table (3): Correlation between serum CRP and both serum amyloid A and salivary CRP in septic group.**

Correlation	Serum CRP (mg/L)	
	R	P value
<b>Salivary CRP (ng/ml)</b>	0.50	0.001*
<b>SAA (µg/ml)</b>	0.70	0.001*

\* Significant at p value<0.05

- CRP: C-reactive protein

**Table (4): Comparison between culture positive (n=20), clinical sepsis (n=20), and control (n=40)] as regard SAA, salivary CRP, serum CRP and outcome.**

Item	Culture positive (n=20)	Clinical sepsis (n=20)	Control (n=40)	P value		
<b>Salivary CRP</b>				<0.001*		
				<b>P1</b>	<b>P2</b>	<b>P3</b>
(ng/ml)	1.8 ±0.5	1.3 ±0.7	0.16±0.6			
Mean ± SD	1.9 (0.6:2.8)	1 (0.7:3)	0.15(0.1:0.3)	0.01*	<0.001*	<0.001*
Median (Range)						
<b>SAA (µg/ml)</b>				<0.001*		
				<b>P1</b>	<b>P2</b>	<b>P3</b>
Mean ± SD	33.7 ±7.8	19.2 ±9.2	3.1±0.8			
Median (Range)	33.2(16 :49.5)	14.5(10.9:46)	3(1.5:4.8)	<0.001*	<0.001*	<0.001*
<b>Serum CRP</b>				<0.001*		
				<b>P1</b>	<b>P2</b>	<b>P3</b>
(mg/L)	52.2 ±35	54.6 ± 40	0.9±2.5			
Mean ± SD	48(0:96)	48(12:96)	0(0:12)	0.94	<0.001*	<0.001*
Median (Range)						
<b>Outcome</b>				0.01*		
Died	4(20%)	3(15%)	0			
Improved	16(80%)	17(85%)	40(100%)			

\* significant at p value<0.05.

P1 mean p value between culture positive group and clinical sepsis.

P2 mean p value between culture positive group and control.

P3 mean p value between clinical sepsis and control.

SD: standard deviation SAA: Serum Amyloid A, CRP: C-reactive protein .

**Table (5): ROC curve analysis of salivary CRP, serum CRP and SAA for prediction of neonatal sepsis.**

Item	Salivary CRP (ng/ml)	Serum CRP (mg/L)	Serum amyloid (µg/ml)
<b>Optimal cut off point</b>	>0.31	>9	>4.6
<b>AUC</b>	1	0.95	1
<b>P value</b>	<0.001*	<0.001*	<0.001*
<b>Sensitivity</b>	100%	92.5%	100%
<b>Specificity</b>	97.5%	95%	95%
<b>PPV</b>	100%	92.5%	100%
<b>NPV</b>	97.5%	97.5%	92.5%

\* Significant at p value<0.05, ROC curve: receiver operating characteristic curve, AUC: area under curve, CRP: C-reactive protein, PPV: positive predictive value, NPV: negative predictive value.

**Table (6): ROC curve analysis of salivary CRP for prediction if serum CRP  $\geq 10$  mg/L.**

Item	Salivary CRP (ng/ml)
<b>Optimal cut off point</b>	>0.65
<b>AUC</b>	0.94
<b>P value</b>	<0.001*
<b>Sensitivity</b>	97%
<b>Specificity</b>	95%
<b>PPV</b>	97%
<b>NPV</b>	95%

ROC curve: receiver operating characteristic curve, AUC: area under curve, PPV: positive predictive value, NPV: negative predictive value, CRP: C-reactive protein

**Table (7): ROC curve analysis of salivary CRP, serum CRP and SAA for prediction of culture positive neonatal sepsis.**

Item	Salivary CRP (ng/ml)	Serum CRP (mg/L)	SAA ( $\mu$ g/ml)
<b>Optimal cut off point</b>	>0.96	>18	>4.4
<b>AUC</b>	0.90	0.77	0.96
<b>P-value</b>	<0.001*	<0.001*	<0.001*
<b>Sensitivity</b>	90%	85%	100%
<b>Specificity</b>	80%	69%	60%
<b>PPV</b>	90%	85%	100%
<b>NPV</b>	80%	69%	60%

\* Significant at p value<0.05, ROC curve: receiver operating characteristic curve, AUC: area under curve, PPV: positive predictive value , NPV: negative predictive value, SAA: Serum Amyloid A , CRP : C-reactive protein

**Table (8): Comparison between full term and preterm neonates regarding salivary CRP, SAA and serum CRP**

Item	Preterm group (n=20)	Full term group (n=20)	P value
<b>Salivary CRP (ng/ml)</b>			
<b>Mean <math>\pm</math> SD</b>	1.4 $\pm$ 0.6	1.7 $\pm$ 0.7	0.26
<b>Median (Range)</b>	1.25 (0.72:2.8)	1.9 (0.6:3)	
<b>SAA (<math>\mu</math>g/ml)</b>			
<b>Mean <math>\pm</math> SD</b>	24.5 $\pm$ 13.7	28.3 $\pm$ 7.8	0.22
<b>Median (Range)</b>	19 (10.9 :49.5)	30.5 (12:40.5)	
<b>Serum CRP (mg/L)</b>			
<b>Mean <math>\pm</math> SD</b>	47 $\pm$ 29.5	60 $\pm$ 34.3	0.23
<b>Median (Range)</b>	48 (0:96)	48 (0:96)	

SAA: Serum Amyloid A , CRP : C-reactive protein

Table (9): Causative organisms in positive blood culture group

Blood culture (N=40)	Descriptive statistics (N%)
Gram negative n, (%)	15 (37.5%)
Klebsiella pneumoniae	12 (30%)
Acinetobacter	3 (7.5%)
Gram positive n, (%)	4 (10%)
MRSA	3 (7.5%)
CONS	1 (2.5%)
Candida Albicans	1 (2.5%)
No growth	20 (50%)




Figure (1): ROC curve analysis of salivary CRP for prediction of neonatal sepsis.




Figure (2): ROC curve analysis of serum amyloid for prediction of neonatal sepsis.




Figure (3): ROC curve analysis of serum CRP for prediction of neonatal sepsis.






Figure (4): ROC curve analysis of salivary CRP for prediction of positive culture sepsis.



**Figure (5):** ROC curve analysis of serum CRP for prediction of positive culture sepsis.



**Figure (6):** ROC curve analysis of serum amyloid for prediction of positive culture sepsis.

## Discussion

The identification of biomarkers for early neonatal sepsis could improve immediate and long-term outcomes, reduce the use of prophylaxis antibiotics, and reduce the risk of infection, pain, and anaemia in sick hospitalised neonates, who often require frequent blood sampling. Our study involved 80 neonates, with a mean gestational age of  $36 \pm 2.3$  and a birth weight of  $2 \pm 0.65$  kg, with 62.6% being females, and Forty healthy sex and age-matched babies selected as a control group. The study found that all cases had late-onset sepsis, with 35% experiencing fever, 12% having tachycardia, 25%

having decreased sucking, 16% having apnea, and 57.5% needing oxygen. The majority of cases improved (82.5%), while only 17.5% died. Salivary CRP is detectable in neonates, and there is a moderate positive correlation with serum CRP, making it a valuable biomarker for diagnosing neonatal sepsis and detecting abnormal serum CRP levels. The study In culture-positive septic groups, there was a significant difference in the amount of CRP in the saliva of cases compared to controls. *Klebsiella pneumoniae* was the most common organism, followed by MRSA and *Acinetobacter*. The cases tested positive

for *Candida albicans* and CONS. The study found a statistically significant difference regarding salivary CRP levels in septic and control neonates, similar to previous studies by Omran et al. [44] and Iyengar et al. [40]. However, Tosson et al. [45] found no significant difference in salivary CRP values between septic and controls, possibly due to the different kits used and population, as their study enrolled only full-term neonates. The study found a moderately positive correlation between salivary CRP and serum CRP ( $r = 0.78$ ;  $p < 0.001$ ), consistent with previous studies by Datla et al., [46] Omran et al. [44] and Iyengar et al. [40]. However, Tosson et al. [45] did not find a statistically significant correlation, possibly due to the different methodology and study population. The study found that the median salivary CRP levels were significantly different between the control, culture-positive cases, and clinical sepsis groups. This difference was statistically significant ( $P < 0.001$ ). Finding aligns with previous

studies by Ramavath et al. [47] and Datla et al. [46]. However, Tosson et al. [45] did not find a significant difference between the three groups, possibly due to differences in the studied population and isolated organisms. Only a few studies have evaluated the predictive value of salivary CRP in neonatal sepsis, with favorable results and variable AUC values. This study found very significant predictability with an AUC of 0.9 for culture-positive sepsis, consistent with Ramavath et al.'s [47] findings. The cut-off values of salivary CRP vary among studies due to different ELISA methods and measuring units. Previous studies predicted serum CRP levels of 10 mg/mL or higher. The time between serum sample collection and salivary sample collection also differs. In our study, we collected salivary samples within 12 hours of collecting serum CRP samples. Methodological differences and time intervals contribute to the different cutoff values reported. We need further large-scale studies to determine the

optimal cut-off value. Currently, there is no published normative data on salivary CRP in healthy neonates. Salivary CRP levels above 0.96 ng/mL and serum CRP levels above 18 mg/L were the best ways to tell if someone had culture-positive sepsis, according to the study. The AUC on the ROC curve analysis was 0.9. Ramavath et al.'s [47] study showed cut-off scores for culture-positive sepsis. The use of Hs-CRP kits, which are more accurate in detecting CRP, could explain why salivary CRP is a reliable predictor of positive blood culture sensitivity, specificity, and PPV in neonates. CRP detection is accurate. It seems that salivary CRP is a good way to tell if someone has culture-positive sepsis, which is in line with what Ramavath et al. [47] found, even though they used different salivary CRP kits. With an AUC of 0.94 and a sensitivity of 97%, salivary CRP was a good way to diagnose CRP levels above 10 mg/L in serum. This aligns with a 2014 study by Iyengar et al. [40], which found

similar accuracy at a cut-off point of 4.84 ng/mL. Results may vary due to population characteristics. The study compared the results of two previous studies, Iyengar et al. [40] and Omran et al. (44) which focused on post-operative neonates with sepsis and full-term neonates, respectively. We can attribute the differences to various pre-processing techniques and assay methods. The incidence of positive blood cultures was 50%, with LOS occurring in 100% of cases. The study found that gram-negative bacteria, predominantly *Klebsiella pneumoniae*, were the most common isolates, accounting for 30% of the sample. This aligns with previous studies, such as Ramavath et al. [47] Hashim et al. [48] and Elmashad et al. [49]. However, Tosson et al. [45] found MRSA to be the most common organism isolated in the septic group. Hammoud et al. [50] found CoNs to be the most common pathogen in LOS. The study's sensitivity and specificity for serum CRP cut-off levels were 92.5% and 95%,

respectively. Similarly, Tosson et al.[45] discovered that a serum CRP cut-off level could diagnose LOS 91% of the time and 100% of the time. Our study had a 92.5% PPV and a 97.5% NPV, indicating that serum CRP has a PPV of 100% and an NPV of 85.7%, similar to Tosson et al.'s findings. [45] However, Brown et al. [51] found that serum CRP is insufficient for accurately diagnosing LOS or guiding antibiotic treatment. The study also compared SAA with other biochemical markers in neonatal sepsis. The correlation between SAA and serum CRP in this study was moderately positive, with  $r = 0.50$ . Agreeing with our results, Mohsen et al. [52] found the correlation between SSA and serum CRP to be significant ( $r = 0.483$ ,  $p = <0.01$ ). The study found that the level of SSA in cases was significantly higher than controls ( $P < 0.001$ ), consistent with previous research. This finding aligns with Malle and De Beer's [53] study, which found an increase in SAA levels as an acute-phase reactant in clinical

practice. Bengnér et al. [54] also found a significant difference in SAA levels between septic cases and controls. Arnon et al. [55] reported that preterm neonates could use SAA for early detection of late-onset sepsis. According to Cetinkaya et al. [42], the increase in SAA in septic neonates at the onset of sepsis was insignificant. We used ROC curves to test how well SAA could diagnose neonatal sepsis. At a cut-off level of  $4.6 \mu\text{g/ml}$ , the test had 100% sensitivity, 95% specificity, 100% PPV, and 92.5% NPV. This aligns with El Mashad et al. [49] study, which found SAA protein as the most sensitive marker. According to Arnon et al. [56] and the PPV of serum CRP was 87%, while the PPV of SAA was 96%, and the PPV of serum CRP in our study was 92.5%. The study found that the diagnostic utility of serum albumin (SAA) for distinguishing between culture-positive and clinical sepsis was better than serum CRP. This finding is consistent with Bourika et al.'s [57] findings, which found similar

diagnostic utility in serum CRP. However, the most significant data on SAA's diagnostic utility in neonatal sepsis comes from a meta-analysis by Yuan et al. [58], which included nine studies with varying cases of neonatal sepsis. The studies assessed the use of SAA for diagnosis in the first suspicion, with sensitivity and specificity ranging from 23%–100% and 44%–100%, respectively. The study found that the diagnostic accuracy of SAA was slightly better than that of CRP, with a pooled sensitivity, specificity, and diagnostic accuracy of 84%, 89%, and 90%, respectively, indicating significant variability among studies. Yuan et al. [58] The study found that cases had significantly lower platelet counts compared to controls ( $p < 0.001$ ), consistent with Omran et al. [59] findings. However, Tosson et al. [45] did not find a significant difference in platelet count between cases and controls, indicating a potential difference in hematological parameters. The study

found a significant increase in TLC in cases compared to controls ( $P = 0.003$ ), consistent with Mubarak et al. [60] findings. However, Tosson et al. [45] and Omran et al. [44] did not find a statistically significant difference.

The study had limitations, including the time required to collect a viable sample from preterm neonates, the exclusion of neonates with oral disease as candida, and the exclusion of neonates on mechanical ventilation due to increased respiratory secretions.

### Conclusions

The study suggests that salivary CRP can be a valuable noninvasive biomarker for late-onset neonatal sepsis diagnosis, with comparable results to SAA and serum CRP. However, we need to conduct further research on sample collection methods, normative values, cost effectiveness, and standardization of assay procedures.

**Data Availability:** The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

### Acknowledgements

The study group is grateful to the NICU team who supported this work

### Author's contributions

Study concept and design: Nagwa Mohamed Sabry Mahmoud, Gamal Baheeg, Manar Anwar Abd-Elaziz, Nageh Shehata Ismail. Data collection : Manar Anwar Abd-Elaziz. Analysis and interpretation of data: Nagwa Mohamed Sabry Mahmoud, Gamal Baheeg, Manar Anwar Abd-Elaziz, Nageh Shehata Ismail. Drafting of the manuscript: Nagwa Mohamed Sabry Mahmoud. Critical revision of the manuscript for important intellectual content: Nagwa Mohamed Sabry Mahmoud, Nagwa Ismail Okaily. Statistical analysis: Nagwa Mohamed Sabry Mahmoud, Gamal Baheeg, Manar Anwar Abd-Elaziz, Nageh Shehata Ismail. laboratory data interpretations, Nagwa Ismail Okaily. All authors read and approved the final manuscript

### Funding

We had not received financial support for the study

### Conflict of interest

We declared no conflict of interest concerning the study.

### Author's details

<sup>1</sup>Pediatric department, Faculty of Medicine, Minia University, Egypt

<sup>2</sup>Clinical pathology department, Faculty of Medicine, Minia University, Egypt

**Date received:** 1<sup>st</sup> June 2024, accepted 10 August 2024

### References

1. Weston E.J., Pondo T.M., Lewis M.M., Martell-Cleary P.M., Morin C., Jewell B., Daily P., Apostol M., Petit S., Farley M., et al. The Burden of Invasive Early-onset Neonatal Sepsis in the United States, 2005–2008. *Pediatr. Infect. Dis. J.* 2011; 30:937–941. doi: 10.1097/INF.0b013e318223bad2.
2. Oza S., Lawn J.E., Hogan D.R., Mathers C., Cousens S.N. Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013. *Bull. World Health Organ.* 2015; 93:19–28. doi: 10.2471/BLT.14.139790.
3. Stoll B.J., Hansen N.I., Adams-Chapman I., Fanaroff A.A., Hintz S.R., Vohr B., Higgins R.D., National Institute of Child Health and Human Development Neonatal Research Network Neurodevelopmental and Growth Impairment Among Extremely Low-Birth-Weight Infants with Neonatal Infection. *JAMA.* 2004; 292:2357–2365. doi:10.1001/jama.292.19.2357.
4. Wynn J.L. Defining neonatal sepsis. *Curr. Opin. Pediatr.* 2016; 28:135–140. doi: 10.1097/MOP.0000000000000315.

5. Boghossian N.S., Page G.P., Bell E.F., Stoll B.J., Murray J.C., Cotten C.M., Shankaran S., Walsh M.C., Laptook A.R., Newman N.S., et al. Late-Onset Sepsis in Very Low Birth Weight Infants from Singleton and Multiple-Gestation Births. *J. Pediatr.* 2013; 162:1120–1124.e1. doi: 10.1016/j.jpeds.2012.11.089.
6. Stoll B.J., Hansen N.I., Sanchez P.J., Faix R.G., Poindexter B.B., Van Meurs K.P., Bizzarro M.J., Goldberg R.N., Frantz I.D., III, Hale E.C., et al. Early onset neonatal sepsis: The burden of group B Streptococcal and E. coli disease continues. *Pediatrics.* 2011; 127:817–826. doi: 10.1542/peds.2010-2217.
7. Mukhopadhyay S., Eichenwald E.C., Puopolo K.M. Neonatal early-onset sepsis evaluations among well-appearing infants: Projected impact of changes in CDC GBS guidelines. *J. Perinatol.* 2013; 33:198–205. doi: 10.1038/jp.2012.96.
8. Kuzniewicz M.W., Walsh E.M., Li S., Fischer A., Escobar G.J. Development and Implementation of an Early-Onset Sepsis Calculator to Guide Antibiotic Management in Late Preterm and Term Neonates. *Jt. Comm. J. Qual. Patient Saf.* 2016; 42:232–239. doi: 10.1016/S1553-7250(16)42030-1.
9. Amare D., Mela M., Dessie G. Unfinished agenda of the neonates in developing countries: Magnitude of neonatal sepsis: Systematic review and meta-analysis. *Heliyon.* 2019;5: e02519. doi: 10.1016/j.heliyon.2019. e02519.
10. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., Lemons J.A., Donovan E.F., Stark A.R., Tyson J.E., et al. Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. *Pediatrics.* 2002; 110:285–291. doi:10.1542/peds.110.2.285.
11. Tsai M.-H., Hsu J.-F., Chu S.-M., Lien R., Huang H.-R., Chiang M.-C., Fu R.-H., Lee C.-W., Huang Y.-C. Incidence, Clinical Characteristics and Risk Factors for Adverse Outcome in Neonates with Late-onset Sepsis. *Pediatr. Infect. Dis. J.* 2014;33: e7–e13. doi: 10.1097/INF.0b013e3182a72ee0.
12. Hofer N., Zacharias E., Müller W., Resch B. Performance of the definitions of the systemic inflammatory response syndrome and sepsis in neonates. *J. Perinat. Med.* 2012; 40:587–590. doi: 10.1515/jpm-2011-0308.
13. Wynn J.L., Wong H.R., Shanley T.P., Bizzarro M.J., Saiman L., Polin R.A. Time for a Neonatal-Specific Consensus

- Definition for Sepsis. *Pediatr. Crit. Care Med.* 2014; 15:523–528. doi: 10.1097/PCC.000000000000157.
- 14.** PrabhuDas M., Adkins B., Gans H., King C., Levy O., Ramilo O., Siegrist C.-A. Challenges in infant immunity: Implications for responses to infection and vaccines. *Nat. Immunol.* 2011; 12:189–194. doi: 10.1038/ni0311-189.
- 15.** Steinberger E., Hofer N., Resch B. Cord blood procalcitonin and Interleukin-6 are highly sensitive and specific in the prediction of early-onset sepsis in preterm infants. *Scand. J. Clin. Lab. Investig.* 2014; 74:432–436. doi: 10.3109/00365513.2014.900696.
- 16.** Chiesa C., Pellegrini G., Panero A., Osborn J.F., Signore F., Assumma M., Pacifico L. C-Reactive Protein, Interleukin-6, and Procalcitonin in the Immediate Postnatal Period: Influence of Illness Severity, Risk Status, Antenatal and Perinatal Complications, and Infection. *Clin. Chem.* 2003; 49:60–68. doi: 10.1373/49.1.60.
- 17.** Morris R., Jones S., Banerjee S., Collinson A., Hagan H., Walsh H., Thornton G., Barnard I., Warren C., Reid J., et al. Comparison of the management recommendations of the Kaiser Permanente neonatal early-onset sepsis risk calculator (SRC) with NICE guideline CG149 in infants  $\geq 34$  weeks' gestation who developed early-onset sepsis. *Arch. Dis. Child. Fetal Neonatal Ed.* 2020; 105:581–586. doi: 10.1136/archdischild-2019-317165.
- 18.** Hershkovich–Shporen C., Guri A., Gluskina T., Flidel-Rimon O. Centers for disease control and prevention guidelines identified more neonates at risk of early-onset sepsis than the Kaiser-Permanente calculator. *Acta Paediatr.* 2022; 111:767–771. doi: 10.1111/apa.16232.
- 19.** Bakhuizen S.E., de Haan T.R., Teune M.J., van Wassenae-Leemhuis A.G., van der Heyden J.L., van der Ham D.P., Mol B.W.J. Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. *Acta Paediatr.* 2014; 103:1211–1218. doi: 10.1111/apa.12764.
- 20.** Porta A., Esposito S., Menson E., Spyridis N., Tsolia M., Sharland M., Principi N. Off-label antibiotic use in children in three European countries. *Eur. J. Clin. Pharmacol.* 2010; 66:919–927. doi: 10.1007/s00228-010-0842-1.
- 21.** Chakkarapani A.A., Russell A.B. Antibiotic stewardship in the neonatal intensive care

- unit. Paediatr. Child Health. 2019; 29:269–273. doi: 10.1016/j.paed.2019.03.004.
- 22.** Lee K.R., Bagga B., Arnold S.R. Reduction of Broad-Spectrum Antimicrobial Use in a Tertiary Children's Hospital Post Antimicrobial Stewardship Program Guideline Implementation. *Pediatr. Crit. Care Med.* 2016; 17:187–193. doi: 10.1097/PCC.0000000000000615.
- 23.** Jong N.B.-D., Van Gemert-Pijnen L., Wentzel J., Hendrix R., Siemons L. Technology to Support Integrated Antimicrobial Stewardship Programs: A User Centered and Stakeholder Driven Development Approach. *Infect. Dis. Rep.* 2017; 9:36–41. doi: 10.4081/idr.2017.6829.
- 24.** Ho T., Buus-Frank M.E., Edwards E.M., Morrow K.A., Ferrelli K., Srinivasan A., Pollock D.A., Dukhovny D., Zupancic J.A., Pursley D.M., et al. Adherence of Newborn-Specific Antibiotic Stewardship Programs to CDC Recommendations. *Pediatrics.* 2018; 142: e20174322. doi: 10.1542/peds.2017-4322.
- 25.** Schulman J., Dimand R.J., Lee H.C., Duenas G.V., Bennett M.V., Gould J.B. Neonatal Intensive Care Unit Antibiotic Use. *Pediatrics.* 2015; 135:826–833. doi: 10.1542/peds.2014-3409.
- 26.** Cotten C.M. Adverse consequences of neonatal antibiotic exposure. *Curr. Opin. Pediatr.* 2016; 28:141–149. doi: 10.1097/MOP.0000000000000338.
- 27.** Sharma D., Farahbakhsh N., Shastri S., Sharma P. Biomarkers for diagnosis of neonatal sepsis: A literature review. *J. Matern. Fetal Neonatal Med.* 2018; 31:1646–1659. doi: 10.1080/14767058.2017.1322060.
- 28.** Kellogg J.A., Ferrentino F.L., Goodstein M.H., Liss J., Shapiro S.L., Bankert D.A. Frequency of low levels bacteremia in infants from birth to two months of age. *Pediatr. Infect. Dis. J.* 1997; 16:381–385. doi: 10.1097/00006454-199704000-00009.
- 29.** Woodford E.C., Dhudasia M.B., Puopolo K.M., Skerritt L.A., Bhavsar M., DeLuca J., Mukhopadhyay S. Neonatal blood culture inoculant volume: Feasibility and challenges. *Pediatr. Res.* 2021; 90:1086–1092. doi: 10.1038/s41390-021-01484-9.
- 30.** Yager P., Edwards T., Fu E., Helton K., Nelson K., Tam M.R., Weigl B.H. Microfluidic diagnostic technologies for global public health. *Nature.* 2006; 442:412–418. doi: 10.1038/nature05064.
- 31.** Pammi M., Flores A., Leeftang M., Versalovic J. Molecular Assays in the
-

- Diagnosis of Neonatal Sepsis: A Systematic Review and Meta-analysis. *Pediatrics*. 2011;128: e973–e985. doi: 10.1542/ peds. 2011-1208.
- 32.** Da Silva O., Ohlsson A., Kenyon C. Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: A critical review. *Pediatr. Infect. Dis. J.* 1995; 14:362–366. doi: 10.1097/ 0000 6454-199505000-00005.
- 33.** Greenberg D.N., Yoder B.A. Changes in the differential white blood cell count in screening for group B streptococcal sepsis. *Pediatr. Infect. Dis. J.* 1990; 9:886–889. doi: 10.1097/00006454-199012000-00006.
- 34.** Escobar G.J., Zukin T., Usatin M.S. Early discontinuation of antibiotic treatment in newborns admitted to rule out sepsis: A decision rule. *Pediatr. Infect. Dis. J.* 1994; 13:860–866. doi: 10.1097/00006454-1994 10000 -00003.
- 35.** Escobar G.J., Li D.K., Armstrong M.A., Gardener M.N., Flock B.F., Verdi J.E., Xiong B., Bergen R. Neonatal sepsis workups in infants  $\geq 2000$  grams at birth: A population-based study. *Pediatrics*. 2000; 106:256–263. doi: 10.1542/peds.106.2.256.
- 36.** Newman T.B., Puopolo K.M., Wi S., Draper D., Escobar G.J. Interpreting Complete Blood Counts Soon After Birth in Newborns at Risk for Sepsis. *Pediatrics*. 2010; 126:903–909. doi: 10.1542/peds.2010-0935.
- 37.** Mussap M, Noto A, Cibecchini F, Fanos V. The importance of biomarkers in neonatology. *Semin Fetal Neonatal Med.* 2013; 18:56–64.
- 38.** Çelik HT, Portakal O, Yiğit Ş, Haşcelik G, Korkmaz A, Yurdakök M. Efficacy of new leukocyte parameters versus serum C-reactive protein, procalcitonin, and interleukin-6 in the diagnosis of neonatal sepsis. *Pediatr Int.* 2016; 58:119–25.
- 39.** Delanghe JR, Speeckaert MM. Translational research and biomarkers in neonatal sepsis. *Clin Chim Acta.* 2015; 451:46–64.
- 40.** Iyengar A, Paulus JK, Gerlanc DJ, Maron JL. Detection and potential utility of C-reactive protein in saliva of neonates. *Front Pediatr.* 2014; 2:131.
- 41.** Liu C, Fang C, Xie L. Diagnostic utility of procalcitonin as a bio- marker for late-onset neonatal sepsis. *Transl Pediatr.* 2020;9(3): 237–242.
- 42.** Cetinkaya M, Oezkan H, Koçksal N, et al. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. *J Perinatol.* 2009; 29(3):225–231.

43. Mithal LB, Palac HL, Yogev R, et al. Cord blood acute phase reactants predict early onset neonatal sepsis in preterm infants. *PLoS One*. 2017;12(1):e 0168677.
44. Omran A, Maaroo A, Saleh MH, Abdelwahab A. Salivary C-reactive protein, mean platelet volume and neutrophil lymphocyte ratio as diagnostic markers for neonatal sepsis. *Jornal de pediatria*. 2018; 94:82-7.
45. Tosson A, Koptan D, Aal RA, Elhady MA. Evaluation of serum and salivary C-reactive protein for diagnosis of late-onset neonatal sepsis: a single center cross-sectional study. *Jornal de Pediatria*. 2021; 97:623-8.
46. Datla S, Kitchanan S, Sethuraman G. Diagnostic reliability of salivary C-reactive protein as an alternative noninvasive biomarker of neonatal sepsis. *Indian Pediatrics*. 2021; 58:745-8.
47. Ramavath C, Katam SK, Vardhelli V, Deshabhotla S, Oleti TP. Examining the Utility of Rapid Salivary C-Reactive Protein as a Predictor for Neonatal Sepsis: An Analytical Cross-Sectional Pilot Study. *Diagnostics*. 2023;13(5):867.
48. Hashim MS, Aboulghar HM, El-Gayar DF, Hamam AO. Evaluation of serum cortisol and ACTH level in neonatal sepsis. *Egypt J Neonatol*. 2004; 3:135-43.
49. Elmashad GM, Elsayed HM, Omar ZA, Badr EA, Omran OM. Evaluation of serum amyloid A protein as a marker in neonatal sepsis. *Menoufia Medical Journal*. 2019; 32(3):1094-8.
50. Hammoud MS, Al-Taiar A, Al-Abdi SY, Bozaid H, Khan A, AlMuhairi LM, et al. Late-onset neonatal sepsis in Arab states in the Gulf region: two-year prospective study. *International Journal of Infectious Diseases*. 2017; 55:125-30.
51. Brown JVE, Meader N, Cleminson J, McGuire W. C-reactive protein for diagnosing late-onset infection in newborn infants. *Cochrane Database of Systematic Reviews*. 2019(1). Accessed 10 Mars 2023.
52. Mohsen L, Mourad I, Iskander S, El-Sahrigy E-MS. Study on diagnostic value of serum amyloid A protein during late-onset sepsis in preterm and full-term neonates. *Australian Journal of Basic and Applied Sciences*. 2012; 6(12):530-6.
53. Malle E, De Beer F. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. *European journal of clinical investigation*. 1996;26(6):427-35.
54. Bengnér J, Quttineh M, Gäddlin P-O, Salomonsson K, Faresjö M. Serum amyloid A—A prime candidate for identification of

neonatal sepsis. Clinical Immunology. 2021; 229:108787.

55. Arnon S, Litmanovitz I, Regev R, Bauer S, Lis M, Shainkin-Kestenbaum R, et al. Serum amyloid A protein is a useful inflammatory marker during late-onset sepsis in preterm infants. Neonatology. 2005;87(2):105-10.

56. Arnon S, Litmanovitz I, Regev R, Lis M, Shainkin-Kestenbaum R et al. Serum amyloid A protein in the early detection of late-onset bacterial sepsis in preterm infants. Journal of Perinatal Medicine. 2002;30(4): 329-32.

57. Bourika V, Hantzi E, Michos A, Margeli A, Papassotiriou I, Siahianidou T. Clinical value of serum amyloid-A protein, high-density lipoprotein cholesterol and apolipoprotein-A1 in the diagnosis and follow-up of neonatal sepsis. The Pediatric Infectious Disease Journal. 2020;39(8):749-55.

58. Yuan H, Huang J, Lv B, Yan W, Hu G, Wang J et al. Diagnosis value of the serum amyloid A test in neonatal sepsis: a meta-

analysis. BioMed research international. 2013; 2013:520294.

59. Omran A, Sobh H, Abdalla MO, El-Sharkawy S, Rezk AR, Khashana A. Salivary and Serum Interleukin-10, C-Reactive Protein, Mean Platelet Volume, and CRP/MPV Ratio in the Diagnosis of Late-Onset Neonatal Sepsis in Full-Term Neonates. Journal of Immunology Research. 2021:4884537.

60. Mubarak MA, Faqihi A, AlQhtani F, Hafiz TA, Alalhareth A, Thagfan FA, et al. Blood Biomarkers of Neonatal Sepsis with Special Emphasis on the Monocyte Distribution Width Value as an Early Sepsis Index. Medicina. 2023;59(8):1425.

**Neonatology Submit your next manuscript to Annals of Journal and take full advantage of:**

- Convenient online submission
- Thorough and rapid peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- No limit as regards tables or figures.
- Open Access research freely available for redistribution

**Submit your manuscript at:**

[www.anj.journals.ekb.eg](http://www.anj.journals.ekb.eg)

**Citation:** Nagwa Mohamed Sabry Mahmoud; Gamal Baheeg Mohamed; Nagwa Ismail Okaily; Manar Anwar Abd El-Aziz; Nageh Shehata Ismail. "Diagnostic Utility of Serum Amyloid A and Salivary C-Reactive Protein in Diagnosis of Late Onset Sepsis in Neonates- A Prospective Case Control Study", Annals of Neonatology, 2025, 7(1):1-26 doi: 10.21608/anj.2024.300074.1094

**Copyright:** Mahmoud et al., 2025. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY-NC-ND) license (4).

